Logo

Albert Parker

Aug 09, 2018

OncoCyte has appointed Albert Parker as its chief operating officer. According to the company, Parker is an attorney and executive with more than 25 years of pharmaceutical, biotech, and healthcare experience. Prior to joining OncoCyte, Parker served as the managing shareholder of GC Legal Advisors, where he represented and advised public and privately held companies, primarily in the life sciences industry. Among other prior roles, Parker has also served as executive VP, general counsel, and corporate secretary at Sunovion Pharmaceuticals, senior VP and chief counsel for Wyeth Pharmaceuticals, and partner at Schnader Harrison Segal & Lewis.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.